Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $250.00 short call and a strike $255.00 long call offers a potential 27.55% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $250.00 by expiration. The full premium credit of $1.08 would be kept by the premium seller. The risk of $3.92 would be incurred if the stock rose above the $255.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 26.32 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Here is What Hedge Funds Think About Eli Lilly and Company (LLY)
Tue, 07 Dec 2021 19:19:25 +0000
Is Eli Lilly and Company (NYSE:LLY) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise […]
10 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors
Tue, 07 Dec 2021 17:53:57 +0000
In this article, we take a look at the 10 pharmaceutical stocks to buy according to Brandon Haley’s Holocene Advisors. You can skip our detailed analysis of Holocene Advisors’ 13F portfolio and go directly to 5 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors. The hedge fund Holocene Advisors was founded and is […]
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
Tue, 07 Dec 2021 17:16:05 +0000
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.
Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19
Tue, 07 Dec 2021 15:26:03 +0000
The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.
AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label
Mon, 06 Dec 2021 15:04:03 +0000
AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.
Also on Market Tamer…
Follow Us on Facebook